128 related articles for article (PubMed ID: 9494588)
1. A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine.
Saunders MP; Salisbury AJ; O'Byrne KJ; Souliotis VL; Varcoe SM; Talbot DC; Kyrtopoulos SA; Harris AL
Anticancer Res; 1997; 17(6D):4677-80. PubMed ID: 9494588
[TBL] [Abstract][Full Text] [Related]
2. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Philip PA; Souliotis VL; Harris AL; Salisbury A; Tates AD; Mitchell K; van Delft JH; Ganesan TS; Kyrtopoulos SA
Clin Cancer Res; 1996 Feb; 2(2):303-10. PubMed ID: 9816173
[TBL] [Abstract][Full Text] [Related]
3. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
Agarwala SS; Ferri W; Gooding W; Kirkwood JM
Cancer; 1999 May; 85(9):1979-84. PubMed ID: 10223239
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.
Cocconi G; Bella M; Calabresi F; Tonato M; Canaletti R; Boni C; Buzzi F; Ceci G; Corgna E; Costa P
N Engl J Med; 1992 Aug; 327(8):516-23. PubMed ID: 1635566
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
7. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
8. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
O'Neill PA; Butt M; Eswar CV; Gillis P; Marshall E
Melanoma Res; 2006 Jun; 16(3):245-8. PubMed ID: 16718271
[TBL] [Abstract][Full Text] [Related]
9. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
11. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
Fierro MT; Bertero M; Novelli M; Appino A; Doveil GC; Colonna S; Bernengo MG
Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
13. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
15. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
16. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
Hwu WJ; Knight RD; Patnana M; Bassett R; Papadopoulos NE; Kim KB; Hwu P; Bedikian A
Melanoma Res; 2010 Dec; 20(6):501-6. PubMed ID: 20859231
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Del Prete SA; Maurer LH; O'Donnell J; Forcier RJ; LeMarbre P
Cancer Treat Rep; 1984 Nov; 68(11):1403-5. PubMed ID: 6541973
[No Abstract] [Full Text] [Related]
18. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
19. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
20. The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen.
Crowell EB; Higa GM
W V Med J; 1993 Jun; 89(6):233-5. PubMed ID: 8322461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]